180 related articles for article (PubMed ID: 16087765)
1. Sudden uncontrollable somnolence and medication use in Parkinson disease.
Avorn J; Schneeweiss S; Sudarsky LR; Benner J; Kiyota Y; Levin R; Glynn RJ
Arch Neurol; 2005 Aug; 62(8):1242-8. PubMed ID: 16087765
[TBL] [Abstract][Full Text] [Related]
2. Sleep attacks, daytime sleepiness, and dopamine agonists in Parkinson's disease.
Paus S; Brecht HM; Köster J; Seeger G; Klockgether T; Wüllner U
Mov Disord; 2003 Jun; 18(6):659-67. PubMed ID: 12784269
[TBL] [Abstract][Full Text] [Related]
3. Predictors of impaired daytime sleep and wakefulness in patients with Parkinson disease treated with older (ergot) vs newer (nonergot) dopamine agonists.
Razmy A; Lang AE; Shapiro CM
Arch Neurol; 2004 Jan; 61(1):97-102. PubMed ID: 14732626
[TBL] [Abstract][Full Text] [Related]
4. Sleepiness in Parkinson's disease: a controlled study.
Brodsky MA; Godbold J; Roth T; Olanow CW
Mov Disord; 2003 Jun; 18(6):668-72. PubMed ID: 12784270
[TBL] [Abstract][Full Text] [Related]
5. Excessive daytime sleepiness and sudden-onset sleep in Parkinson disease: a survey by the Canadian Movement Disorders Group.
Hobson DE; Lang AE; Martin WR; Razmy A; Rivest J; Fleming J
JAMA; 2002 Jan 23-30; 287(4):455-63. PubMed ID: 11798367
[TBL] [Abstract][Full Text] [Related]
6. Double-blind, single-dose, cross-over study of the effects of pramipexole, pergolide, and placebo on rest tremor and UPDRS part III in Parkinson's disease.
Navan P; Findley LJ; Jeffs JA; Pearce RK; Bain PG
Mov Disord; 2003 Feb; 18(2):176-80. PubMed ID: 12539211
[TBL] [Abstract][Full Text] [Related]
7. Risk factors for somnolence, edema, and hallucinations in early Parkinson disease.
Biglan KM; Holloway RG; McDermott MP; Richard IH;
Neurology; 2007 Jul; 69(2):187-95. PubMed ID: 17620552
[TBL] [Abstract][Full Text] [Related]
8. Risk factors for the development of pedal edema in patients using pramipexole.
Kleiner-Fisman G; Fisman DN
Arch Neurol; 2007 Jun; 64(6):820-4. PubMed ID: 17420306
[TBL] [Abstract][Full Text] [Related]
9. An open-label conversion study of pramipexole to ropinirole prolonged release in Parkinson's disease.
Lyons KE; Pahwa R
Mov Disord; 2009 Oct; 24(14):2121-7. PubMed ID: 19768728
[TBL] [Abstract][Full Text] [Related]
10. An exploratory retrospective evaluation of ropinirole-associated psychotic symptoms in an outpatient population treated for restless legs syndrome or Parkinson's disease.
Stoner SC; Dahmen MM; Makos M; Lea JW; Carver LJ; Rasu RS
Ann Pharmacother; 2009 Sep; 43(9):1426-32. PubMed ID: 19690226
[TBL] [Abstract][Full Text] [Related]
11. Conversion from dopamine agonists to pramipexole. An open-label trial in 227 patients with advanced Parkinson's disease.
Linazasoro G;
J Neurol; 2004 Mar; 251(3):335-9. PubMed ID: 15015015
[TBL] [Abstract][Full Text] [Related]
12. Increased risk of somnolence with the new dopamine agonists in patients with Parkinson's disease: a meta-analysis of randomised controlled trials.
Etminan M; Samii A; Takkouche B; Rochon PA
Drug Saf; 2001; 24(11):863-8. PubMed ID: 11665873
[TBL] [Abstract][Full Text] [Related]
13. Excessive daytime sleepiness in Parkinson disease: is it the drugs or the disease?
Gjerstad MD; Alves G; Wentzel-Larsen T; Aarsland D; Larsen JP
Neurology; 2006 Sep; 67(5):853-8. PubMed ID: 16966550
[TBL] [Abstract][Full Text] [Related]
14. Cardiac valve regurgitation with pergolide compared with nonergot agonists in Parkinson disease.
Dewey RB; Reimold SC; O'Suilleabhain PE
Arch Neurol; 2007 Mar; 64(3):377-80. PubMed ID: 17353380
[TBL] [Abstract][Full Text] [Related]
15. [Multiple latency test in a patient with episodes of sleep induced by pergolide].
Jiménez-Jiménez FJ; Velasco I; de Toledo M; Sayed Y; Zurdo J; Ortí-Pareja M
Rev Neurol; 2002 Jun 16-30; 34(12):1140-1. PubMed ID: 12134281
[TBL] [Abstract][Full Text] [Related]
16. [Sleep attacks and pergolide mesylate].
García Ruiz PJ; Hernández J; Cantarero S; Fanjul S
Neurologia; 2001 Feb; 16(2):92. PubMed ID: 11257938
[No Abstract] [Full Text] [Related]
17. Dopamine receptor gene polymorphisms in Parkinson's disease patients reporting "sleep attacks".
Rissling I; Geller F; Bandmann O; Stiasny-Kolster K; Körner Y; Meindorfner C; Krüger HP; Oertel WH; Möller JC
Mov Disord; 2004 Nov; 19(11):1279-84. PubMed ID: 15390060
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of sleep and driving performance in six patients with Parkinson's disease reporting sudden onset of sleep under dopaminergic medication: a pilot study.
Möller JC; Stiasny K; Hargutt V; Cassel W; Tietze H; Peter JH; Krüger HP; Oertel WH
Mov Disord; 2002 May; 17(3):474-81. PubMed ID: 12112193
[TBL] [Abstract][Full Text] [Related]
19. Dopamine agonists and cardiac valvulopathy in Parkinson disease: a case-control study.
Yamamoto M; Uesugi T; Nakayama T
Neurology; 2006 Oct; 67(7):1225-9. PubMed ID: 17030757
[TBL] [Abstract][Full Text] [Related]
20. Excessive daytime sleepiness and sleep episodes in Japanese patients with Parkinson's disease.
Suzuki K; Miyamoto T; Miyamoto M; Okuma Y; Hattori N; Kamei S; Yoshii F; Utsumi H; Iwasaki Y; Iijima M; Hirata K
J Neurol Sci; 2008 Aug; 271(1-2):47-52. PubMed ID: 18436241
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
